[A24-60] Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141
Last updated 20.06.2024
Project no.:
A24-60
Commission:
Commission awarded on 07.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with previously untreated diffuse large B-cell lymphoma
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-60_en
| Project no. | Title | Status |
|---|---|---|
| A23-141 | Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.